You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 11 No. 4, October 1964 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Cortical Alterations Due to Methionine Sulfoximine

Ultrastructure During Seizure Activity

BASIL HARRIS, MD

Arch Neurol. 1964;11(4):388-407.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Introduction

In 1946, Mellanby1 showed that the nitrogen trichloride treatment used for bleaching (agenizing) flour acted on proteins to produce a toxic product that caused running fits (so-called canine hysteria) in dogs. This toxic substance, isolated and later synthesized by Bentley2-4 and by Misani and Reiner,5,6 proved to be methionine sulfoximine,* an analogue and competitive antimetabolite of methionine. It has been shown to produce seizures in a number of species. Earlier workers, using agenized flour, have shown EEG changes but not seizures in monkeys7-9 and neither of these changes in epileptic patients.10 Seizures have been prevented by giving large protective doses of methionine before commencing an experiment.11 The observations based on agenized flour administration have been shown to be less reliable since a calculated maximum . . . [Full Text PDF of this Article]


Author Affiliations

ST. LOUIS

Division of Neurosurgery, Department of Neurology and the Beaumont-May Institute of Neurology, Washington University School of Medicine.

Work supported by Program-Project grant NB 04513-01, National Institute of Neurological Diseases and Blindness, and in part by the Allen P. and Josephine B. Green Foundation.


Footnotes

Submitted for publication April 27, 1964; accepted May 5.

The DL-methionine-DL-sulfoximine was purchased from the California Corporation for Biochemical Research, Los Angeles.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1964 American Medical Association. All Rights Reserved.